Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	27.34B -17.7%
Revenue (ttm)	8.58B +28.2%
Net Income	1.00B +5.2%
EPS	1.82 +4.2%
Shares Out	545.26M
PE Ratio	27.50
Forward PE	25.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	341,600
Open	50.70
Previous Close	49.78
Day's Range	49.58 - 50.95
52-Week Range	45.50 - 87.10
Beta	0.64
Analysts	Strong Buy
Price Target	102.90 (+105.18%)
Earnings Date	Aug 21, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 4,082
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY

Analyst Summary

According to 8 analysts, the average rating for 2696 stock is "Strong Buy." The 12-month stock price target is $102.90, which is an increase of 105.18% from the latest price.

Price Target

$102.90

(105.18% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error